MustGrow Biologics is closing its Canadian marketing and distribution arm, NexusBioAg, to focus resources on scaling production of its TerraSante biofertilizer in the US. TerraSante, an organic product derived from mustard, has seen demand exceed supply throughout 2025 and into 2026, especially among large US commercial farmers. MustGrow raised $2 million in equity financing and secured a $2 million credit facility to boost production, leveraging third-party manufacturers instead of building its own plant. The company is also exploring global partnerships to expand TerraSante internationally, positioning it as a sustainable alternative for soil and crop health in modern agriculture.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
